Some welcome reassuring news!
In this cohort study, 668 older adults with hematologic malignant neoplasms and 1994 matched participants without cancer had similar rates of cognitive decline before diagnosis, surrounding the time of diagnosis, and after diagnosis when the competing risk of death was accounted for.
Meaning
These findings suggest the cognitive trajectory of older adults diagnosed with hematologic malignant neoplasm parallels the trajectory seen in normal aging.
jamanetwork.com/journals/ja...
Within the HMN cohort, the most common diagnoses were myeloproliferative neoplasm (127 patients [19.0%]), chronic leukemia (106 patients [15.9%]), and multiple myeloma (97 patients [14.5%]).
Why the concern?
HMN biology and treatments may impact cognition differently from solid tumors. First, HMN and its treatments cause more cytopenias, which are associated with increased fatigue, decreased physical activity, and cardiovascular risk, which may impact cognition.14-16 Second, since HMNs are systemic diseases affecting the immune and hematopoietic systems, their disease biology may influence cognition independent of treatment, as has been suggested in chronic lymphocytic leukemia and lymphomas.17-20 Lastly, unlike solid tumors, which in early stages may be treated with surgery or radiation, most HMNs are treated with systemic therapy, which is associated with higher CRCI risk.
Neil